TABLE OF CONTENTS. Drug Shortages
|
|
- Giles Wood
- 5 years ago
- Views:
Transcription
1 TABLE OF CONTENTS Drug Shortages 1 Medication Safety: New Gemini Neonatal and Pediatric Standard Drips Methotrexate Warning in Gemini HIV/AIDS Therapeutic Guidelines 2 HIV/AIDS Drugs on the Horizon 4 P& T Committee Formulary Action 6 Drug Shortages While the incidence of drug product shortages has been gradually increasing since the early 1990 s, health care professionals nationwide began reporting an escalation of the problem in In response, the American Society for Health-System Pharmacists (ASHP) launched a Drug Product Shortages Management Resource Center on its Web site ( Since its launch in 2001, there has been an increase in the number of drug shortage bulletins and updates issued on the site, which is maintained by the University of Utah s Drug Information Service. Purportedly, the Web site resource center receives approximately 60 reports of shortages each month. Currently, more than 50 products are represented in bulletins on the site, and information about availability is provided for another 20 products. Furthermore, three months into 2002, the Food and Drug Administration (FDA) identified eight medically necessary drug products as being in short supply and 11 other products as having limited distribution. Drug product shortages stem from several factors including a shortage of raw materials, manufacturing problems, voluntary recalls, and the FDA halting a manufacturer s processing plant. Additional shortages have occurred as pharmaceutical manufacturers discontinue drug product lines. Drug shortages have the potential to negatively impact patient care through several mechanisms including: Disruption of medical procedures Less than optimal therapeutic alternatives Prolonging patients hospital stays Increasing medication errors and adverse drug events Furthermore, health care providers face the ongoing challenge to provide equivalent medications to patients and to conserve and ration inventories. Recently, the American Medical Association (AMA) and ASHP collaborated in bringing together a group of medical experts to explore solutions to the ongoing drug shortages problem. Various stakeholders representing the FDA, trade associations for research-based and generic pharmaceuticals manufacturers and distributors, purchasing group organizations, drug wholesalers, American Society of Anesthesiologists, the American Hospital Association, the Institute of Medicine and the Department of Veterans Affairs, assembled to identify and categorize potential causes and solutions to the problem of drug shortages. In short, participants at the meeting cited the need for improvement in the areas of: Communications Manufacturing Distribution and inventory management Regulation and enforcement Economic incentives Research and study Better communication, including notifications about imminent shortages and future drug availability, topped the list of possible solutions for prevention or effective resolution of drug shortages. One strategy involved requiring manufacturers to notify the FDA of potential product shortages. Overall, the group acknowledged the importance of a centralized resource to provide physicians, pharmacists, and other health care providers with ready access to up-to-date, reliable information about alternative therapies. Readers who require additional information are referred to the published summary of the session available at Drug Shortages at University of Illinois Hospital It is recognized that ongoing drug shortages can present a serious threat to patient care and safety. Therefore, the Department of Hospital Pharmacy Services promotes preparedness for such occurrences by employing several procedures as described below: Information regarding current and impending drug shortage information is sought through literature search and web site (ie. ASHP, FDA, etc.) on a regular basis. This includes direct communication with the manufacturer for information including reason for the shortage, a product release date, direction for ordering drugs on allocation or for emergency supplies. 1 2
2 All attempts are made to obtain needed supplies. This includes obtaining supply from alternative suppliers/wholesalers or ordering allocated or emergency supplies from the manufacturer. Manufacturers sometimes require physicians to initiate the request based on individual patient s need. Literature search and drug use evaluation (if necessary) is performed for the purpose of identifying clinically appropriate uses of a drug, the lowest optimal dose, strategies to decrease drug waste, alternative products and priority uses for extreme shortages. Based on the extent of the shortage, the availability of alternatives, and results of a drug use evaluation (if performed), a plan is developed to restrict use, reduce waste or select an alternative product. A plan to restrict use of drug is developed by consulting literature, web sites, physician experts who use the product and other local hospitals. Strategies are also planned to avoid inappropriate use or dosing confusion of alternative drugs. Drug supply may be removed from nursing unit floor stock or other non-pharmacy storage areas when necessary. Drug is dispensed from the pharmacy in accordance with the developed restricted use plans. All medical center personnel are alerted to the shortage, possible substitutes and potential adverse events. UIC Drug Shortages Update Critical Shortage: Glucococorticoids for injection betamethasone, hydrocortisone, methylpredisolone ü Use oral agents whenever possible. ü Consider dexamethasone inj. only for patients unable to take oral medications. ü Reserve methylprednisolone inj. for critical indications such as spinal cord injuries or exacerbations of multiple sclerosis. ü Reserve betamethasone inj. for use in obstetric patients. Other Drug Shortages: Limited supply on backorder Isoniazid inj. Diazepam inj. Benztropine inj. Out of stock Clonidine inj. Diazoxide inj. HibTiter Meruvax II Methohexital inj. Neomycin oint. Piperacillin injection Prevnar Prochlorperazine inj. Streptokinase inj. Zinc oxide paste Medication Safety New Gemini Neonatal and Pediatric Standard Drips New Neonatal and Pediatric common IV orders are available under the IV Solutions clinical category in PowerChart. Click the Common Drips - Adult and Neonate/Peds folder to order. There are standard orders for neonatal electrolyte bags based on infusion rate and line access and other medications that include normal starting doses with appropriate infusion rates based on weight. New pediatric IVs include standard ArtLine and CVP IV orders. These new IV orders should facilitate proper ordering of IVs for neonatal and pediatric patients. Methotrexate warning in Gemini In response to an alert from the Institute of Safe Medication Practices, clinicians ordering oral methotrexate on the Gemini patient care system will receive the following alert: DEATHS HAVE BEEN REPORTED WITH DAILY ADMINISTRATION OF ORAL METHOTREXATE WHERE WEEKLY DOSING WAS INTENDED. Please choose an appropriate dosing frequency for the indication This alert will fire to the ordering clinician to prompt a double-check that the right frequency is chosen for the patient s indication. An additional alert fires to the pharmacist on the PharmNet system to make them aware to check the medication frequency for appropriateness as well. HIV/AIDS Therapeutic Guidelines The guidelines for human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) change frequently. This is due to new and changing information about the disease, which calls for revising and updating the treatment guidelines, to ensure optimal therapeutic outcomes in patients. There are biological markers that detect the activity of HIV in the body. One such marker is the CD4 cell count, and the other marker is the HIV viral load. CD4 cells (called helper-t cells) are important to the immune system. When a large number of these cells are destroyed, AIDS develops. These markers help to assess the risk of disease progression to AIDS, and to monitor response to therapy. The restoration of the number and function of both CD4 and CD8 cells during HIV-1 replication has resulted in dramatic reductions in morbidity and mortality. The goal of therapy in HIV patients is to prolong life while suppressing viral replication. The optimal time to initiate therapy remains in question. However, as suggested by the results of a recently completed cohort study, the major determinant of initiating therapy appears to be the CD4 count. Results from this study suggest an increase in mortality when antiretroviral therapy is initiated in patients with CD4 counts below 200/µL compared with initiation at higher levels. Therefore, the International AIDS Society- USA Panel has recently updated their recommendations on when antiretroviral therapy should be initiated, and what guidelines should be utilized. The Panel now recommends 2
3 that therapy with highly active antiretroviral therapy (HAART) be initiated at CD4 counts higher than 200 cells/µl. There is however, still some debate as to what level above 200 cells/µl therapy should be initiated. In primary HIV infection, physicians must thoroughly consider the risk and benefits of starting antiretroviral therapy for CD4 counts above the 200/µL range, and make individualized informed decisions based on the patient s immunologic status, as well as the patient s willingness to initiate an often complex drug-regimen. For patients with established infection but who are asymptomatic, the recommendation for treatment is based on both the CD4 count and the viral load. Due to the high risk of opportunistic infections, therapy should be initiated in patients who have late disease and/or symptomatic HIV infection with a persistent CD4 count of <200 cells/µl, or who have been diagnosed with AIDS or severe recurrent HIV related illnesses or tumor. There are three classes of antiretroviral agents currently available: Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) which are zidovudine (AZT, ZDV), didanosine (ddi), zalcitabine (ddc), stavudine (d4t), lamivudine (3TC), abacavir (ABC) and the nucleotide reverse transcriptase inhibitor (NtRTI), tenofovir; Non-nucleoside reverse transcriptase inhibitors (NNRTI) which are efavirenz (EVF), nevirapine (NVP), and delavirdine (DLV); Protease inhibitors (PI) which are indinavir, ritonavir, nelfinavir, saquinavir, amprenavir, and lopinavir+ritonavir (Kaletra). Although no single agent or regimen has been identified as curative against HIV, combinations of these agents have been shown to be potent inhibitors of viral replication, reducing the virus to below detectable levels. In general, there are 3 different combination regimens for the initial treatment of an established HIV infection: PI (with or without low-dose ritonavir) + NRTIs NNRTI + 2 NRTIs 3 NRTIs (patients with low viral loads and adherence concerns). There is no optimal drug regimen, and therapy must be individualized based on specific patient criteria. Factors to consider when selecting agents for use include, efficacy and durability of antiretroviral activity, tolerability and adverse effects, drug regimen convenience, requirements, and potential drug interactions (see table 1). Monitoring parameters include CD4cell and viral load counts, complete drug adherence, drug resistance testing, and drug concentration monitoring. Clinical efficacy is associated with a decrease in viral load and an increase in CD4 cell count. Treatment naïve patients typically experience at least one treatment failure within the first year of therapy. Individuals fail therapy for different reasons including; adherence and tolerability of the regimen(s), and baseline virologic or immunologic status. Therapy should be changed based on the initial antiretroviral regimen (see table 2). Table 1. Recommended antiretroviral agents for initial treatment of HIV infection. (Antiretroviral drug regimens inlude one choice each from columns A and B of this table. Drug are listed in alphabetical order.) Recommendation Column A Column B Strongly recommended Alternative recommendations No Recommendation; insufficient data Not Recommended- Should not be offered Efavirenz Indinavir Nelfinavir Ritonavir + indinavir Ritonavir/lopinavir (Kaletra ) Ritonavir + saquinavir (softgel or hardgel capsules) Abacavir Amprenavir Delavirdine Nelfinavir+saquinavir softgel capsules Nevirapine Ritonavir Saquinavir softgel capsules Didanosine + lamivudine Stavudine + didanosine Stavudine + lamivudine Zidovudine + didanosine Zidovudine + lamivudine Zidovudine+zalcitabine Hydroxyurea in combination with antiretroviral drugs Ritonavir + amprenavir Ritonavir + nelfinavir Tenofovir Monotherapy with any agent (except in pregnancy) Saquinavir hard gelatin capsule Stavudine + zidovudine (Invirase)-except in combination Zalcitabine + didanosine with ritonavir Zalcitabine + lamivudine Zalcitabine + stavudine From: CDC Guidelines for using antiretroviral agents, MMWR 2002;51(no. RR-7)
4 Table 2. Antiretroviral Regimens And Management Strategies For Suspected Treatment Failure Initial Regimen Failure 2 NRTIs plus an NNRTI Change Both NRTIs and add a ritonavir boost PI component if not part of original regimen or Change to 2 PIs 2 NRTIs plus a PI Change the 2 NRTI components and add an NNRTI or 2 NRTIs plus 2 PIs or 2 NRTIs plus an NNRTI plus 1 or 2 PIs 3 NRTI 2 NRTIs plus an NNRTI or 2 NRTIs plus 1 or 2 PIs or 2 NRTIs plus an NNRTI plus 1 or 2 PIs or Consider adding a nucleotide reverse transcriptase inhibitor (NtRTI) Fixed-Combination Products Kaletra (Lopinavir + ritonavir) is a fixed combination of two protease inhibitors: ritonavir, decreases metabolism and increases the plasma concentrations of lopinavir. The antiretroviral activity of the combination is due to lopinavir since ritonavir is not present in a therapeutic dosage. In general, Kaletra is administered orally twice daily with. Trizivir contains the fixed combination of 3 nucleoside analogs (abacavir sulfate, lamivudine, zidovudine). The agent abacavir sulfate (Ziagen) has been associated with fatal hypersensitivity reactions in approximately 3% to 5% of patients, and should be discontinued as soon as a hypersensitivity reaction is suspected. Symptoms associated with abacavir hypersensitivity include fever, rash, fatigue, abdominal pain/gastrointestinal symptoms, cough, dyspnea, and pharyngitis.trizivir should not be reintroduced following an initial hypersensitivity reaction, as severe or fatal hypersensitivity reactions can occur within hours after restarting therapy with abacavir. In general, the recommended oral dose of Trizivir for adults and adolescents is 1 tablet twice daily. Nucleotide Reverse Transcriptase Inhibitor Viread (tenofovir disoproxil fumarate, [tenofovir DF] Gilead Sciences) is a nucleotide analog recently approved for use in combination with other antiretroviral agents for the treatment of HIV infection. Tenofovir DF should be reserved for use in patients currently receiving antiretroviral treatment and experiencing resistance, treatment failure or in salvage therapy. Tenofovir DF requires initial diester hydrolysis for conversion to tenofovir, and subsequent phosphorylation to form tenofovir diphosphate and in this form it has a prolonged half-life, which allows for its once daily dosing. It inhibits the activity of HIV reverse transcriptase by competing with the natural substrate deoxyadenosine 5 -triphosphate and, after incorporation into the DNA, by DNA chain termination. The risk-benefit ratio has not been established in antiretroviral naïve patients; studies are ongoing in this population. The recommended dose of tenofovir DF is 300mg orally taken once daily, preferably with a full meal that contains some fat. Drug interactions include increase in concentrations of didanosine when given concurrently with tenofovir DF. Other interactions include cidofovir, ganciclovir, acyclovir, valacyclovir, and valganciclovir. These drugs can increase the concentrations of tenofovir DF by competing for tubular secretion or by their reduction in renal function. The most common adverse events are diarrhea, nausea, vomiting, and flatulence. Renal impairment has been reported with the use of tenofovir DF, especially in patients with underlying systemic or renal disease, or in those taking nephrotoxic agents. Some adverse events that were reported voluntary with post-approval use of Viread include asthenia, pancreatitis, dizziness, dyspnea, hypophosphatemia lactic acidosis, rash, elevated creatinine, renal insufficiency, and kidney failure. The reports were from an unknown population size so frequencies could not be determined. Reports of lactic acidosis and severe hepatomegaly with steatosis have been documented, with the most data reported in females. Risk factors for this seem to be obesity, prolonged exposure to nucleosides, and known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors for liver disease. Treatment with Viread should be withheld in patients with clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity. Its role in therapy is for use in combination with other antiretrovirals in patients who have clinically progressed disease. Drugs on the Horizon There are currently a total of 16 FDA-approved antiretroviral agents; however, several antiretroviral drugs are currently under investigation. The following lists comprise investigational antiretroviral agents in the currently available drug classes: Nucleoside reverse transcriptase inhibitors (NRTIs) Emtricitabine (aka FTC; brand: Coviracil) Lodenosine (aka F-ddA) DOTC (aka BCH 10652) Amdoxovir (aka DAPD) D-D4FC DPC 817. Non-nucleoside reverse transcriptase inhibitors (NNRTs) Emivirine (aka MKC 442; brand: Coactinon) DPC 083, Capravirine (aka AG1549 or S-1153) Calanolide A TMC 125 (aka R165335). Protease inhibitors (PIs) Tipranavir (aka PNU ) Atazanavir (aka BMS ) GW (aka VX-175) Mozenavir (aka DMP 450) TMC 126 or TMC 114 DPC 681 & 684. Cross- resistance, intolerance, and serious long-term side effects are associated with the available classes of antiretroviral drugs. Efforts to develop drugs that target HIV molecular entities other than NRTIs, NNRTIs, or PIs are in progress. Integrase inhibitors and fusion inhibitors are potential new classes of antiretroviral drugs that may become available in the near future. 4
5 Integrase inhibitors: (DCQA/DCTA, Zintevir [aka AR 177]) Mechanism of action: HIV-1 integrase, the enzyme that inserts the double-stranded viral DNA copy of the RNA genome into the chromosomes of a human infected cell, is inhibited and viral replication is shut down. Like reverse transcriptase and protease, integrase is absolutely essential for viral replication. HIV mutants with inactive integrase enzymes can infect cells and even produce (via reverse transcriptase) viral DNA, but because this new DNA cannot then be integrated into cellular DNA, no new viruses are produced. Fusion inhibitors: (Pentafuside [aka T-20], T-1249, PRO 542) Mechanism of action: bind to HIV envelop protein, gp 120, Generic name Brand Food effect/alcohol effect Major/severe adverse drug reactions & special instructions Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Abacavir (ABC) Ziagen Take without regard to Fatal hypersensitivity -DO NOT RECHALLENGE Didanosine (ddi) Videx EC -Alcohol increases ABC level by 41% Taken on an empty stomach -buffered formulation -pancreatitis, peripheral neuropathy Lamivudine (3TC) Epivir Avoid alcohol Take without regard to Generally well tolerated Stavudine (d4t) Zerit Take without regard to Dose-dependent peripheral neuropathy, pancreatitis Zalcitabine (ddc) Hivid Take without regard to Severe peripheral neuropathy, oral ulcers Zidovudine (AZT, ZDV) Retrovir Take without regard to Bone marrow suppression, anemia, myopathy Zidovudine + lamivudine Combivir Take without regard to Bone marrow suppression, anemia, myopathy Abacavir + zidovudine + lamivudine Trizivir Take without regard to Bone marrow suppression, anemia, myopathy, fatal hypersensitivity DO NOT RECHALLENGE Tenofovir disoproxil fumarate Viread Take with a meal -nucleotide reverse transcriptase inhibitor Fatal ADR: lactic acidosis and severe hepatomegaly with steatosis have been reported. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Delavirdine Rescriptor Take without regard to Efavirenz Sustiva Avoid taking after high fat meals Nevirapine Protease inhibitors (PIs) Amprenavir Indinavir Viramune Agenerase Crixivan Take without regard to Take with or without meals, but avoid high fat meals Take on empty stomach or light snack. Nelfinavir Viracept Take with Diarrhea Ritonavir Norvir Take with Saquinavir hard gel cap Saquinavir soft gel cap Invirase Fortovase Take without regard to Take with Rash, Stevens-Johnson syndrome (SJS), increased transaminases, headache Rash, central nervous symptoms (dizziness, insomnia, abnormal dreams), increased transaminases, contraindicated in pregnancy Rash, SJS, increased transaminases, hepatitis Stepped dose (200mg qd x14 days then 200mg bid thereafter) Oral solution contains propylene glycol; contraindicated in pregnant women and children < 4 years old, patients with hepatic or renal failure, & patients treated with disulfiram or metronidazole. Gastrointestinal, rash Patients must be well hydrated, and should be instructed to drink 1.5 liters of fluid/day Gastrointestinal, nephrolithiasis, hyperbilirubinemia Refrigerate capsules; refrigeration of oral solution is not necessary Taste perversion, paresthesias, increased triglycerides, elevated CPK and uric acid Refrigerate soft gel capsule (SGC) Elevated transaminase enzymes, acute hyperglycemia Refrigerate capsules until they are dispensed. Capsules stored at room temperature should be used within 2 Lopinavir + ritonavir Kaletra Take with months. Oral solution contains 42% alcohol. Pancreatitis, hepatic toxicity, hyperlipidemias, and hyperglycemia Empty = take on an empty stomach, two hours before or after 5 Light meal = not high in calories, fat or protein, e.g. toast +jelly, crackers, corn flakes + skim milk
6 to prevent HIV virus from binding to CD4+ cell surface. The HIV virus can enter into CD4+ cells by different ways: -With viral envelope protein, gp 120, HIV virus is able to attach to the cell surface of the CD4+ molecule. -HIV may change the structure of its gp120 in order to bind the chemokine co-receptors (CCR5 or CXCR4) on the surface of CD4+ molecule for cell signaling. -By changing the structure of gp41, another viral envelope protein, HIV virus is able to fuse with CD4+ cell surface. Chemokine Receptor Antagonists: (T-22, AOP-Rantes, TAK-779, NSC651016) Mechanism of action: chemokine receptor antagonists include CCR5 and CXCR4 inhibitors. They prevent the second step in viral entry by blocking gp120 from binding to chemokine co-receptors, either CCR5 or CXCR4. Cardiac abnormalities such as QT prolongation and abnormal conduction have been observed during clinical development. Other new classes: Hydroxyurea-like compounds: BCX-34 (purine nucleoside phosphorylase inhibitor), Didox (ribonucleotide reductase inhibitor), VX497 (inosine monophosphate dehydrogenase inhibitor). Immune modulators: HE2000 Interleukin 2 alpha interferon Another limitation of currently available antiretroviral therapy involves the complexity of the regimens due to the high pill burden and dosing frequency. There is a new trend to develop once-daily dosing regimens to facilitate compliance. Efavirenz 600 mg, amprenavir 1200 mg plus ritonavir 200 mg, and lamivudine 300 mg are currently FDA-approved for once-daily dosing, and several other agents including stavudine, abacavir, lopinavir/ritonavir, and saquinavir plus ritonavir are under investigation for this purpose. Deletions (cont.) Pindolol 20mg tablet Piroxicam Plicamycin Deletions cont. Prazosin 2mg, 5mg capsule Rose bengal Secretin 75 unit/ml injection Tranexamic acid Trioxsalen CONTRIBUTORS: Ijeoma Nwazue, PharmD candidate Hoang Nguyen, BS Pharm, PharmD Candidate Connie Larson, PharmD Jamie Paek, PharmD Mariela Diaz-Linares, PharmD Editors: Linda Kay, PharmD, MS Candidate Amy Lodolce, PharmD, BCPS P&T COMMITTEE FORMULARY ACTIONS Additions Voriconazole (200mg tab, inj) Restricted, ID Consult Required Piperacillin/Tazobactam (3.375gm, 4.5gm inj) Restricted, Adult/Peds Oncology or ID, ICU Line Extensions Secretin 16mcg injection Changes in Restrictions Nifedipine IR capsules Restricted, Pediatrics, OB/Gyne, Cath Lab Deletions Due to low use or manufacturer discontinuation Methazolamide Metyrapone Mexiletine Nafarelin Naphazoline Naphazoline/antazoline Orphenadrine Phenazopyridine 200mg tablet
Medscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection
Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Generic Name (Abbreviation) / Trade Name Abacavir (ABC) / Ziagen Trizivir with ZDV + 3TC Epzicom with 3TC Didanosine (ddi)
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationQuick Reference Guide to Antiretrovirals. Guide to Antiretroviral Agents
Author: Malte Schütz, MD June 1, 2002 Quick Reference Guide to Antiretrovirals Regular updates to this publication are posted on the Medscape Web site at http://hiv.medscape.com/updates/quickguide. Please
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationThe Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project. ARV Dosing in End Stage Renal Disease
The Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project ARV Dosing in End Stage Renal Disease 1. Jayasekara, D., Aweeka, F. T., Rodriguez, R., Kalayjian, R. C., Humphreys, M. H.,
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationTerapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos
Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos (Antiretroviral Therapy Present and Future Prospects of Antiretroviral Drugs in Initial and Salvage Therapy)
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationPage 1 of 5 ENLGLISH / ESPAÑOL / PORTUGUÉS / FRANÇAIS Share 3 Drug Chart for HIV Treatment CURRENT EDITION ABOUT SENSE BACK ISSUES MSMGF HOME CONTACT US There are a number of antiretroviral (ARV) medications
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationHIV epidemiology since HIV in the United States. HIV Transmission
HIV epidemiology since 1999 8% increase in HIV diagnoses Men who have sex with men (MSM) increased 14% Heterosexual increased 10% IVDU decrease about 30% Young Black MSM 15% incidence HIV in the United
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationHuman Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV
More informationHIV - Life cycle. HIV Life Cyle
Human Immunodeficiency Virus Retrovirus - integrated into host genome ne single-strand RA 7,000 bases HIV1 > HIV2 > HIV0 Pathology Destruction of CD4+ T lymphocytes Loss of immune function pportunistic
More informationHIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options
STRATEGIES FOR THIRD LINE HIV THERAPY issues to consider when faced with few drug options A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Most people living
More information104 MMWR December 17, 2004
104 MMWR December 17, 2004 TABLE 8. Substantial pharmacokinetic drug-drug interactions for drugs used in the treatment of opportunistic Drugs Interacting with Mechanism/effects Recommendations Acyclovir
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationC h a p t e r 5 5 HIV Therapy Where are We Now?
C h a p t e r 5 5 HIV Therapy Where are We Now? AK Tripathi Professor of Medicine, Physician & Haemato-Oncologist, King George s Medical College, Lucknow Introduction Human Immunodeficiency Virus type
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationWOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM
WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM ID LABEL HERE ---> VERSION DATE 10/01/07 - - - VISIT #: FORM COMPLETED BY: A1. DATE OF BLOOD DRAW: / / M D Y A2. Do you take
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationHIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time
STRATEGIES FOR FIRST LINE HIV THERAPY issues to think about when going on therapy for the first time A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Deciding
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute
ADAP Monitoring Provider Prescribing Patterns Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute WEBINAR ETIQUETTE All questions or comments can be shared either via the
More informationDaclatasvir (Daklinza ) Drug Interactions with HIV Medications
Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationUnderstanding Viruses CHAPTER 38. Antiviral Agents. Understanding Viruses (cont'd) Viral Infections (cont'd) Viral Infections.
Understanding Viruses CHAPTER 38 Antiviral Agents Viral replication A virus cannot replicate on its own It must attach to and enter a host cell It then uses the host cell s energy to synthesize protein,
More informationDescovy. (emtricitabine, tenofovir alafenamide) New Product Slideshow
Descovy (emtricitabine, tenofovir alafenamide) New Product Slideshow Introduction Brand name: Descovy Generic name: Emtricitabine, tenofovir alafenamide (TAF) Pharmacological class: Nucleoside analog reverse
More informationREIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO
REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO Ont. Drug Distr. Ontario Drug Benefit/Trillium: Other Formulary (F/A) Limited Use (Section 16) Antiretrovirals AZT 100 mg capsules NRTIs (single): Abacavir,
More informationOctober 26-28: Training Day 1
Peer Linkage and Re-Engagement of HIV- Positive Women of Color October 26-28: Training Day 1 Peer Linkage and Re -Engagement of HIV - Positive Women of Color Convening Training Trainers Today: Alicia Downes
More informationHIV and AIDS. Shan Nanji
HIV and AIDS Shan Nanji HIV 2 Description: Enveloped Positive Sense HIV 3 Structural Genes: Cleavage of gp160 leads to formation of ENV: Gp120: attachment to host CD4 T Cell Gp41: GAG (p24) Capsid protein
More informationTreatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)
Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if
More informationVemlidy. (tenofovir alafenamide) New Product Slideshow
Vemlidy (tenofovir alafenamide) New Product Slideshow Introduction Brand name: Vemlidy Generic name: Tenofovir alafenamide Pharmacological class: Nucleoside analogue (reverse transcriptase inhibitor) Strength
More informationImportant Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers
Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication For Healthcare Providers About TRUVADA for a PrEP Indication INDICATION AND PRESCRIBING CONSIDERATIONS TRUVADA,
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationOdefsey. (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow
Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow Introduction Brand name: Odefsey Generic name: Emtricitabine, rilpivirine, tenofovir alafenamide (TAF) Pharmacological
More informationMedication Errors Focus on the HIV-Infected Patient
Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation
More informationEfavirenz, stavudine and lamivudine
efavirenz, stavudine, lamivudine: 1 efavirenz, stavudine and lamivudine First line ART treatment for HIV infection Efavirenz, stavudine and lamivudine efavirenz, stavudine, lamivudine: 2 Slide 1 Information
More informationGenotyping and Drug Resistance in Clinical Practice. Case Studies
Genotyping and Drug Resistance in Clinical Practice Case Studies 12/02 40 year old Hispanic male Dx with HIV 1995 + Hx of PCP > 1x, HepC Medication history: AZT, Crixivan, Videx EC, Sustiva, Zerit, Ziagen,
More informationREVIEW No Assessment of safety a. Have all relevant studies on safety been included Yes X No (if no, please provide reference and information)
Expert peer review on application for addition of fixed dose combination formulations of antiretroviral medications in the EML (Adults) REVIEW No. 2 Abacavir + lamivudine (ABC+ 3TC) Tablet (dispersible):
More informationHIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
More informationAntiviral Agents DEPARTEMEN FARMAKOLOGI & TERAPEUTIK FK USU. 06 August
Antiviral Agents Dr. Yunita Sari Pane, MS DEPARTEMEN FARMAKOLOGI & TERAPEUTIK FK USU 06 August 2009 1 VIRUSES Obligate intracellular parasites Consist of a core genome in a protein shell and some are surrounded
More informationJuly 2006 HIV/AIDS Update Part 2 Volume 28 Number 7. W-F Professional Associates, Inc. 400 Lake Cook Rd., Suite 207 Deerfield, IL
W-F Professional Associates, Inc. 400 Lake Cook Rd., Suite 207 Deerfield, IL 60015 847-945-8050 Jully 2006 HIV/AIDS Update Part 2 707-000-06-007-H02 IN THIS LESSON WE DISCUSS ANTIRETROVIRAL THERAPY, COMBINATION
More informationConcomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.
Avifanz Tablet Description Avifanz is the brand name for Efavirenz. Efavirenz, a synthetic antiretroviral agent, is a non-nucleoside reverse transcriptase inhibitor. While Efavirenz is pharmacologically
More informationFluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids
Supportive therapy Summary of interactions Table 1. Summary of potential interactions between antiretroviral agents and supportive therapy Interactions with enzyme inhibitors (protease inhibitors and elvitegravir/cobicistat)
More informationRecommended dosing for pediatric patients (6 months to 12 years of age) 1. Dose based on lopinavir component* 1.25 ml ml
Abbott Virology 100 Abbott Park Road Abbott Park, IL 60064 KALETRA 100/25 mg tablets NDC #0074-0522-60 Dear Healthcare Provider: Introducing a new strength of KALETRA (lopinavir/ritonavir): 100/25 mg tablets
More informationNATAPNATIONAL. HIV 102: Care & Treatment AIDS TREATMENT ADVOCACY PROJECT. Origins of HIV. Table of Contents. National AIDS Treatment Advocacy Project
National AIDS Treatment Advocacy Project HIV 102: Care & Treatment Written by: Jose Castro, MD University of Miami, Miller School of Medicine, Miami, FL Editorial Contributions by: Jules Levin 580 BROADWAY,
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS
ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS - 2014 Alabama s ADAP formulary offers a minimum of one medication from each HIV antiretroviral class approved by the U.S. Food and Drug Administration (FDA).
More informationObjectives. HIV Treatment in Recently In 1996 the introduction of protease inhibitors decreasing the death rate of those infected by 50%.
Objectives Identify modes HIV transmission and methods of prevention. HIV Treatment in 2010 Lisa D. Inge, Pharm.D., BCPS, AAHIVE Assistant Director, Jacksonville Campus Clinical Assistant Professor University
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationwhat's with it? GOT TO DO [Pharmacokinetics] [Pharmacokinetics] Non-Nukes and PIs: Do They Play Well Together? / Top 3 Websites Winter 2005
Winter 2005 what's PK [Pharmacokinetics] [Pharmacokinetics] GOT TO DO with it? IN THIS SPECIAL ISSUE: ABC's of Pharmacokinetics (PK) / The Nukes, Non-Nukes and PIs: Do They Play Well Together? / Top 3
More informationYear 2002 Paper two: Questions supplied by Jo 1
Year 2002 Paper two: Questions supplied by Jo 1 Question 9 A 37 year old man with known human immunodeficiency virus (HIV) infection for 10 years presents with severe renal colic for which he has no prior
More informationRecommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and
Recommendations for Use of Antiretroviral s in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States, June 23, 2004, CDC and updated
More informationDrug Treatment Program Update
Drug Treatment Program Update As of March 211 Drug Treatment Program Update A key component of the Centre s mandate is to monitor the impact of HIV/AIDS on British Columbia. The Centre provides essential
More informationAnti-viral drugs. Certain viruses multiply in the cytoplasm but others do in the nucleus Most multiplication take place before diagnosis is made
Anti-viral Drugs Viruses have no cell wall and made up of nucleic acid components Viruses containing envelope antigenic in nature Viruses are obligate intracellular parasite They do not have a metabolic
More informationMedChem 401~ Retroviridae. Retroviridae
MedChem 401~ Retroviridae Retroviruses plus-sense RNA genome (!8-10 kb) protein capsid lipid envelop envelope glycoproteins reverse transcriptase enzyme integrase enzyme protease enzyme Retroviridae The
More informationAppropriate Use & Safety Edits
Appropriate Use & Safety Edits Envolve Pharmacy Solutions provides a variety of safety edits to promote the use of the right medication, in the right patient, at the right time. These edits are routinely
More informationA Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs
ADDRESSING GAPS IN INNOVATION FOR NEGLECTED PATIENTS: DNDI ANDPEDIATRIC HIV/AIDS Rachel Cohen, Regional Executive Director, DNDi North America Proposals for a Global Innovation System that Responds to
More informationA Genetic Test to Screen for Abacavir Hypersensitivity Reactions
The Future of Pharmacogenetics in HIV Clinical Care A Genetic Test to Screen for Abacavir Hypersensitivity Reactions Evan Collins & Misty Bath CANAC/ACIIS 15 th Annual Conference Vancouver, BC April 2007
More informationAnti-viral drugs. Certain viruses multiply in the cytoplasm but others do in the nucleus Most multiplication take place before diagnosis is made
Anti-viral Drugs Viruses have no cell wall and made up of nucleic acid components Viruses containing envelope antigenic in nature Viruses are obligate intracellular parasite They do not have a metabolic
More informationJune 2004 HIV/AIDS Update Part H02
W-F Professional Associates, Inc. 400 Lake Cook Rd., Suite 207 Deerfield, IL 60015 847-945-8050 June 2004 HIV/AIDS Update Part 2 707-000-04-006-H02 THIS LESSON, COMBINED WITH THE MAY 2004 LESSON, FULFILLS
More informationThe Hospitalized HIV+ Patient
The Hospitalized HIV+ Patient Danny Toub MD dannyt@srheathcenters.org October 8, 2012 Santa Rosa Family Medicine Residency List 3 ways of risk-stratifying known or suspected HIV+ inpatients Perform differential
More informationJULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet
JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationZalcitabine 2-3 -dideoxycytidine, ddc TUD DaMocles SoSe 15
Zalcitabine 2-3 -dideoxycytidine, ddc TUD DaMocles SoSe 15 Nina Drechsler, Christoph Drexler, Robin Dursun, Malte Eckert Graphic 1: Zalcitabine Table of Contents Content 1.... Introduction 1 2.... Properties
More informationNOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
More informationHIV/AIDS Update 2007
HIV/AIDS Update 2007 Joanne J. Orrick, Pharm.D., BCPS Clinical Assistant Professor University of Florida Faculty, Florida/Caribbean AIDS Education and Training Center orricjj@ufl.edu www.faetc.org orricjj@ufl.edu
More informationNew Anti-HIV Therapies
Date: 1/03 Information, Inspiration and Advocacy for People Living with HIV/AIDS New Anti-HIV Therapies Compared to previous years, advances in the field of HIV antiviral research today are few and far
More informationTRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. Training Guide for Healthcare Providers
TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication Training Guide for Healthcare Providers About TRUVADA for a PrEP indication to reduce the risk of sexually acquired HIV-1 infection in high-risk
More informationnevirapine, stavudine and lamivudine
nevirapine, stavudine and lamivudine Information on starting treatment with: nevirapine (NVP) + stavudine (d4t) + lamivudine (3TC) Nevirapine, stavudine and lamivudine (non-fixed dose) 2 Lead in dosing
More informationPROGRESSIVE MULTI-FOCAL LEUKOENCEPHALOPATHY
PROGRESSIVE MULTI-FOCAL LEUKOENCEPHALOPATHY learn about the symptoms, diagnosing and treating this relatively rare brain condition associated with aids A PUBLICATION FROM Information, Inspiration and Advocacy
More informationAdherence Strategies for Older Adults. AIDS Community Research Initiative of America (ACRIA)
Adherence Strategies for Older Adults AIDS Community Research Initiative of America (ACRIA) June 2008 Modular Objectives By the end of the module, participants will be able to: Define adherence Be able
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More information(609) (650) (609) (650)
Bristol-Myers Squibb Contacts Gilead Sciences Contacts Eric Miller, Media James Loduca, Media (609) 252-7981 (650) 522-5908 Kathy Baum, Media Susan Hubbard, Investors (609) 252-4227 (650) 522-5715 John
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationTreatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand
Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity
More informationYOU CAN NOW DOWNLOAD MISPLACED LESSONS FROM OUR WEBSITE (WWW.WFPROFESSIONAL.COM).
W-F Professional Associates, Inc. 400 Lake Cook Rd., Suite 207 Deerfield, IL 60015 847-945-8050 June 2002 HIV/AIDS Update Part 2 707-000-02-006-H02 YOU CAN NOW DOWNLOAD MISPLACED LESSONS FROM OUR WEBSITE
More informationNothing to disclose.
Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital HIV UPDATE FOR THE PRIMARY CARE PROVIDER Nothing to disclose. 1 Outline Epidemiology Screening / testing for HIV
More informationAntiretroviral Therapy
Antiretroviral Therapy Scott M. Hammer, M.D. 1986 1990 ZDV monorx 1990 1995 Alternative NRTI monorx Combination NRTI Rx Introduction of NNRTI s Antiretroviral resistance Pathogenetic concepts Evolution
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine
More informationTORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION
TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman
More informationNON-OCCUPATIONAL POST EXPOSURE PREVENTION. when you think you were exposed to hiv within the past three days
NON-OCCUPATIONAL POST EXPOSURE PREVENTION when you think you were exposed to hiv within the past three days A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 November 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 November 2010 ISENTRESS 400 mg, film-coated tablet B/60 (CIP code: 383 084-8) Applicant: MSD-CHIBRET raltegravir
More informationGuidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters
Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationHIV Treatment. Why do I need to know about HIV treatment?
HIV Treatment Why do I need to know about HIV treatment? As a person living with HIV, you have to decide which HIV treatment is right for you, using the best information available. The more informed you
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2012 EDURANT 25 mg film-coated tablets B/30 (CIP code: 219 472-9) Applicant: JANSSEN-CILAG rilpivirine ATC code
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationAIDS 101: From Abstinence to Zidovudine
AIDS 101: From Abstinence to Zidovudine Frank Romanelli 1 College of Pharmacy, University of Kentucky, 800 Rose Street, C11 7, Lexington KY 40536 PROLOGUE Development of the Acquired Immune Deficiency
More informationRE: NDA # Truvada (emtricitabine and tenofovir disoproxil fumarate) Tablets MACMIS # 18360
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Joyce Q. Acbay Director, Regulatory Affairs 333 Lakeside Drive
More informationTHE STAGING AND MEDICATION OF HIV INFECTION
Supplement A: WHO CLINICAL STAGING THE STAGING AND MEDICATION OF HIV INFECTION Clinical Stage 1 Clinical Stage 2 Clinical Stage 3 Clinical Stage 4 Asymptomatic Persistent generalized lymphadenopathy Moderate
More information